|
Tweet | ||
144 ! | Mon, 8/10/2015, 8:30 AM - 10:20 AM | CC-610 | |
Novel Design and Statistical Modeling in Early Development of Oncology Drugs — Contributed Papers | |||
Biopharmaceutical Section , Biometrics Section | |||
Chair(s): Peipei Shi, Eli Lilly and Company | |||
8:35 AM | Comparisons of Cure Rate Models — Fang Fang, Merrimack Pharmaceuticals ; Liping Huang, Bayer HealthCare Pharmaceuticals | ||
8:50 AM | Evaluation of Treatment Efficacy Using a Bayesian Mixture Piecewise Linear Model of Longitudinal Biomarkers — Lili Zhao, University of Michigan ; Dai Feng, Merck Research Laboratories ; Marc Buyse, Hasselt University ; Brian Neelon, University of South Carolina | ||
9:05 AM | Modeling Framework for Longitudinal Tumor Size in Oncology Clinical Trials — Tianle Hu, Eli Lilly and Company ; Honglu Liu, Eli Lilly and Company | ||
9:20 AM | Modeling Tumor Growth in Preclinical Studies — Yuefeng Lu | ||
9:35 AM | Statistical Evaluation of Dose Expansion Cohorts in Phase I Trials — Matthew Schipper | ||
9:50 AM | Bayesian Random Forest for Predictive Biomarkers Identification — Wei Zheng, Sanofi ; Yuefeng Lu, Sanofi ; Yang Zhao, Sanofi | ||
10:05 AM | Phase I/II Oncology Study Design with Dose Escalation and Concomitant Dose Expansion — Chaofeng Liu |
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.